Developer docs
API playgroundTry for free, no card

Search company profiles

SpectronRx

Full company profile

uuid00077lz

Namestring
SpectronRx
Legal namestring
SpectronRx
Websiteurl
spectronrx.com
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIndianapolis, United States
HQ citystring
Indianapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical contract manufacturing, medical isotope production, radiolabeling services, GMP manufacturing services, nuclear medicine isotopes
Industry4 codes
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Radiopharmaceutical Contract Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Contract Manufacturing Services
TypeProfessional Services
Description

Fee-for-service contract manufacturing for radiopharmaceutical development, from preclinical through full commercialization. Services include shared or full-service GMP manufacturing, mAb/nanobody/peptide labeling, and analytical services. Revenue is earned through project-based contracts, equipment leasing, and scalable sharing programs.

spectronrx.com
2Isotope Production and Sales
TypeLicensing Royalties
Description

Production and global distribution of high-purity medical isotopes (Ac-225, Lu-177, Cu-64, I-131, and others) to pharmaceutical clients. SpectronRx produces isotopes in-house and procures from global supplier network for worldwide delivery.

spectronrx.com
3Master Services Agreements (MSAs)
TypeManaged Services
Description

Long-term manufacturing agreements with pharmaceutical clients such as Plus Therapeutics for GMP manufacturing, technology transfer, and clinical supply. These structured MSAs provide recurring revenue from multi-year engagements.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Supply Chain, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Project-based CDMO services — pricing determined by scope, phase, and isotope requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Service scope ranges from early-phase (Phase 0) through commercialization, with costs varying by molecule complexity, isotope selection, regulatory pathway, and manufacturing scale.

spectronrx.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SpectronRx is a radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from early-phase development through commercialization. Core offerings include GMP manufacturing, mAb/nanobody/peptide radiolabeling, global isotope procurement and in-house production (including proprietary Actinium-225), regulatory assistance through FDA approval, theranostics engineering, analytical services, and worldwide cold-chain logistics for short-lived radiopharmaceuticals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 300,000 patient doses supported annually across current facilities
+3 more records
Product overview1 text field

SpectronRx is a radiopharmaceutical CDMO (Contract Development and Manufacturing Organization) providing end-to-end solutions for radiopharmaceutical development and manufacturing. The core offering combines CDMO/RDMO services with isotope procurement and production capabilities, supplemented by mAb/nanobody/peptide labeling, regulatory assistance, worldwide logistics, GMP manufacturing, and theranostics engineering. The company operates multiple facilities across Indiana, Connecticut, and Belgium, supporting over 300,000 patient doses annually with expansion plans for over one million square feet of production space.

Product and service6 records
1CDMO/RDMO Services
CategoryContract Manufacturing Services
Description

Contract Development and Manufacturing Organization (CDMO) and Radiopharmaceutical Development and Manufacturing Organization (RDMO) services providing end-to-end solutions for radiopharmaceutical development from early phase through full commercialization, including shared or full-service GMP manufacturing, technology transfer, and scale-up for pharmaceutical and biotech clients.

2Isotope Procurement and Production
CategoryMedical Isotope Supply
Description

Global procurement and in-house production of high-purity medical isotopes including Actinium-225, Iodine-123/131, Copper-64/67, Lutetium-177, Indium-111, Zirconium-89, Cerium-134, Radium-226, Lead-212, Gallium-68, Germanium-68, Strontium-82, and Fluorine-18 for diagnostic imaging and radioligand therapies, distributed globally to six continents.

3Regulatory Assistance
CategoryRegulatory Consulting
Description

Regulatory consulting services specializing in regulatory pathway development from Phase 0 through full FDA approval (including IND filing), facilities design, compliance consulting, equipment validation, cleanroom design and validation, and quality systems support for radiopharmaceutical developers.

4Worldwide Logistics
CategoryLogistics Services
Description

Cold chain logistics services for safe, effective, on-time delivery of radiopharmaceuticals at any temperature worldwide, with chain-of-custody telemetry monitoring to support global distribution of short-lived radioactive drugs.

5Theranostics Engineering
CategoryEngineering Services
Description

Specialized engineering services for designing custom shielding, isotope handling automation, and associated equipment for theranostic applications, supported by an in-house engineering team for specialized tooling and equipment design.

6Analytical Services
CategoryAnalytical and Quality Control Services
Description

Drug- and molecule-specific analytical services and comprehensive hardware instrumentation analysis for quality control, analytical method validation, manufacturing process validation, and routine clinical supply support.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

Plus Therapeutics entered into a Master Services Agreement with SpectronRx for GMP manufacturing activities as a second manufacturing site to support late-stage clinical supply for REYOBIQ (rhenium Re186 obisbemeda). The partnership enables on-demand Rhenium-186 isotope production and drug manufacturing within the same facility, strengthening Plus Therapeutics' multi-partner supply chain.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Bicycle Therapeutics established strategic partnerships including a collaboration with SpectronRx and UKNNL to develop a bespoke 212Pb generator for targeted alpha therapy in cancer treatments. The partnership aims to create an end-to-end supply chain for Bicycle's wholly owned radiopharmaceutical pipeline, extracting and processing radioisotopes from reprocessed uranium.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Bicycle Therapeutics entered a 15-year contract with the UK Nuclear Decommissioning Authority for access to reprocessed uranium (up to 400 tonnes) for development of radiopharmaceuticals for cancer treatment. SpectronRx collaborates with UKNNL under this arrangement to extract and process radioisotopes for targeted alpha therapy.

4UK National Nuclear Laboratory (UKNNL)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-16
Description

UKNNL collaborates with Bicycle Therapeutics and SpectronRx to extract and process radioisotopes from reprocessed uranium for targeted alpha therapy. UKNNL's nuclear expertise combined with SpectronRx's manufacturing capabilities enables development of bespoke radioisotope generators for the Bicycle Radioconjugate pipeline.

businesswire.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Existing supply chain partner within Plus Therapeutics' multi-partner supply network for radiopharmaceutical manufacturing and isotope supply. Part of the established partner ecosystem for clinical supply reliability.

Strategic tierSupportingTypeTechnology or Integration
Description

Existing supply chain partner providing Rhenium-186 isotope supply within Plus Therapeutics' multi-partner supply chain ecosystem. Telix supplies isotopes used in SpectronRx's manufacturing activities for REYOBIQ clinical supply.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpectronRx

Radiopharmaceutical Contract Manufacturingspectronrx.com

SpectronRx firmographics

Firmographics
Name
SpectronRx
Legal name
SpectronRx
Website
https://spectronrx.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

SpectronRx industry classification

Industry
Product category
Radiopharmaceutical Contract Manufacturing
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Radiopharmaceutical contract manufacturing
  • Medical isotope production
  • Radiolabeling services
  • GMP manufacturing services
  • Nuclear medicine isotopes

Where SpectronRx is headquartered

Location

Headquarters

HQ city
Indianapolis
HQ country
United States
HQ region
North America

Offices5 records

Markets served

SpectronRx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. CDMO Contract Manufacturing Services: Fee-for-service contract manufacturing for radiopharmaceutical development, from preclinical through full commercialization. Services include shared or full-service GMP manufacturing, mAb/nanobody/peptide labeling, and analytical services. Revenue is earned through project-based contracts, equipment leasing, and scalable sharing programs.
  2. Isotope Production and Sales: Production and global distribution of high-purity medical isotopes (Ac-225, Lu-177, Cu-64, I-131, and others) to pharmaceutical clients. SpectronRx produces isotopes in-house and procures from global supplier network for worldwide delivery.
  3. Master Services Agreements (MSAs): Long-term manufacturing agreements with pharmaceutical clients such as Plus Therapeutics for GMP manufacturing, technology transfer, and clinical supply. These structured MSAs provide recurring revenue from multi-year engagements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CDMO services — pricing determined by scope, phase, and isotope requirements

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

SpectronRx product offering

Product offering

Core offering

SpectronRx is a radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from early-phase development through commercialization. Core offerings include GMP manufacturing, mAb/nanobody/peptide radiolabeling, global isotope procurement and in-house production (including proprietary Actinium-225), regulatory assistance through FDA approval, theranostics engineering, analytical services, and worldwide cold-chain logistics for short-lived radiopharmaceuticals.

Product overview

SpectronRx is a radiopharmaceutical CDMO (Contract Development and Manufacturing Organization) providing end-to-end solutions for radiopharmaceutical development and manufacturing. The core offering combines CDMO/RDMO services with isotope procurement and production capabilities, supplemented by mAb/nanobody/peptide labeling, regulatory assistance, worldwide logistics, GMP manufacturing, and theranostics engineering. The company operates multiple facilities across Indiana, Connecticut, and Belgium, supporting over 300,000 patient doses annually with expansion plans for over one million square feet of production space.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDMO/RDMO Services Contract Development and Manufacturing Organization (CDMO) and Radiopharmaceutical Development and Manufacturing Organization (RDMO) services providing end-to-end solutions for radiopharmaceutical development from early phase through full commercialization, including shared or full-service GMP manufacturing, technology transfer, and scale-up for pharmaceutical and biotech clients.
  • Isotope Procurement and Production Global procurement and in-house production of high-purity medical isotopes including Actinium-225, Iodine-123/131, Copper-64/67, Lutetium-177, Indium-111, Zirconium-89, Cerium-134, Radium-226, Lead-212, Gallium-68, Germanium-68, Strontium-82, and Fluorine-18 for diagnostic imaging and radioligand therapies, distributed globally to six continents.
  • Regulatory Assistance Regulatory consulting services specializing in regulatory pathway development from Phase 0 through full FDA approval (including IND filing), facilities design, compliance consulting, equipment validation, cleanroom design and validation, and quality systems support for radiopharmaceutical developers.
  • Worldwide Logistics Cold chain logistics services for safe, effective, on-time delivery of radiopharmaceuticals at any temperature worldwide, with chain-of-custody telemetry monitoring to support global distribution of short-lived radioactive drugs.
  • Theranostics Engineering Specialized engineering services for designing custom shielding, isotope handling automation, and associated equipment for theranostic applications, supported by an in-house engineering team for specialized tooling and equipment design.
  • Analytical Services Drug- and molecule-specific analytical services and comprehensive hardware instrumentation analysis for quality control, analytical method validation, manufacturing process validation, and routine clinical supply support.

Quantifiable outcome

  • Over 300,000 patient doses supported annually across current facilities
  • +3 more outcomes

Companies that use SpectronRx

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

SpectronRx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SpectronRx partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • Plus TherapeuticscoreStrategic or Co-development Partner · 23 April 2026Plus Therapeutics entered into a Master Services Agreement with SpectronRx for GMP manufacturing activities as a second manufacturing site to support late-stage clinical supply for REYOBIQ (rhenium Re186 obisbemeda). The partnership enables on-demand Rhenium-186 isotope production and drug manufacturing within the same facility, strengthening Plus Therapeutics' multi-partner supply chain.
  • Bicycle TherapeuticscoreStrategic or Co-development Partner · 16 December 2025Bicycle Therapeutics established strategic partnerships including a collaboration with SpectronRx and UKNNL to develop a bespoke 212Pb generator for targeted alpha therapy in cancer treatments. The partnership aims to create an end-to-end supply chain for Bicycle's wholly owned radiopharmaceutical pipeline, extracting and processing radioisotopes from reprocessed uranium.
  • UK Nuclear Decommissioning Authority (NDA)coreStrategic or Co-development Partner · 16 December 2025Bicycle Therapeutics entered a 15-year contract with the UK Nuclear Decommissioning Authority for access to reprocessed uranium (up to 400 tonnes) for development of radiopharmaceuticals for cancer treatment. SpectronRx collaborates with UKNNL under this arrangement to extract and process radioisotopes for targeted alpha therapy.
  • UK National Nuclear Laboratory (UKNNL)coreTechnology or Integration · 16 December 2025UKNNL collaborates with Bicycle Therapeutics and SpectronRx to extract and process radioisotopes from reprocessed uranium for targeted alpha therapy. UKNNL's nuclear expertise combined with SpectronRx's manufacturing capabilities enables development of bespoke radioisotope generators for the Bicycle Radioconjugate pipeline.
  • RadiomedixsupportingStrategic or Co-development PartnerExisting supply chain partner within Plus Therapeutics' multi-partner supply network for radiopharmaceutical manufacturing and isotope supply. Part of the established partner ecosystem for clinical supply reliability.
  • Telix PharmaceuticalssupportingTechnology or IntegrationExisting supply chain partner providing Rhenium-186 isotope supply within Plus Therapeutics' multi-partner supply chain ecosystem. Telix supplies isotopes used in SpectronRx's manufacturing activities for REYOBIQ clinical supply.

Scale indicators6 records

Recent moves9 records

Expansion highlights5 records

SpectronRx competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

SpectronRx social profiles

Digital presence

SpectronRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpectronRx leadership team

Management profile

Number of profiles

Profiles4 records

SpectronRx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpectronRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpectronRx

What does SpectronRx do?

SpectronRx is a radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from early-phase development through commercialization. Core offerings include GMP manufacturing, mAb/nanobody/peptide radiolabeling, global isotope procurement and in-house production (including proprietary Actinium-225), regulatory assistance through FDA approval, theranostics engineering, analytical services, and worldwide cold-chain logistics for short-lived radiopharmaceuticals.

Is SpectronRx a public or private company?

SpectronRx is a private company. It is classified as private equity controlled and is currently operating.

When was SpectronRx founded?

SpectronRx was founded in 2004. It employs 101 to 250 people.

Where is SpectronRx based?

SpectronRx is headquartered in Indianapolis, United States, in the North America region.

How does SpectronRx make money?

Three revenue lines are on record. CDMO Contract Manufacturing Services are the primary driver. The others are isotope Production and Sales and master Services Agreements (MSAs).

Does SpectronRx have an API?

No public API is recorded for SpectronRx.

What industry is SpectronRx in?

SpectronRx's product category is Radiopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacePlus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial RolloutPlus Therapeutics reported Q1 2026 net loss of $6.9 million and cash balance of $15.1 million. The company added a fourth national payer for CNSide, expanding coverage to about 81 million lives, and received FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas.GlobeNewswirePlus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™Plus Therapeutics initiated manufacturing activities with SpectronRx under a Master Services Agreement to support GMP pivotal trial readiness for REYOBIQ. The MSA includes technology transfer and on-demand manufacturing at SpectronRx's Indiana facility, with Rhenium-186 supplied by Telix Pharmaceuticals. The company aims to complete manufacturing scale-up for late-stage clinical supply by 2026.Stock TitanPlus Therapeutics begins REYOBIQ GMP transferPlus Therapeutics announced the initiation of manufacturing activities and technology transfer with SpectronRx under a Master Services Agreement to support late-stage clinical manufacturing of Rhenium-186 and REYOBIQ for CNS cancers. SpectronRx's Indiana facility will serve as a second GMP manufacturing site alongside Radiomedix, with Telix Pharmaceuticals supplying the Rhenium-186 isotope, strengthening the company's multi-partner supply chain infrastructure. The partnership supports Plus Therapeutics' 2026 target milestone to complete manufacturing scale-up for late-stage clinical supply needs and expands production capacity for the radiotherapeutic program.GlobeNewswirePlus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™Plus Therapeutics has initiated manufacturing activities with SpectronRx as a second GMP manufacturing site to support late-stage clinical supply for its radiopharmaceutical candidate REYOBIQ (rhenium Re186 obisbemeda). The partnership enables on-demand Rhenium-186 isotope production and drug manufacturing within the same facility, strengthening the company's multi-partner supply chain that already includes Radiomedix and Telix Pharmaceuticals. This development advances Plus Therapeutics toward its 2026 target milestone for completing manufacturing scale-up to serve clinical trial needs and support future commercialization.FinSMEsSpectronRx Raises $85M in FinancingSpectronRx, an Indianapolis-based radiopharmaceutical contract development and manufacturing organization (CDMO/CMO), has raised $85 million in financing from OrbiMed. The company intends to use the funds to scale production capacity, enhance its CDMO and CMO capabilities, and establish commercial-ready isotope supply. The announcement follows the company's recent acquisition of an additional 14 acres and construction of a new 150,000-square-foot production facility at its Grissom Aeroplex campus.VentureburnSpectronRx Secures $85M for Radiopharmaceutical GrowthSpectronRx raised $85 million in funding from OrbiMed to expand its radiopharmaceutical manufacturing capacity in Indiana, addressing the global shortage of therapeutic isotopes used in cancer treatments. The expansion includes building a large manufacturing campus capable of supporting over 300,000 patient doses annually, with a focus on logistics and supply chain improvements.Endpoints NewsDrug sub­stance mak­er rais­es prices due to en­er­gy cri­sis; Spec­tron­RX gets $85MBASF Pharma Solutions raised prices for drug ingredients citing the ongoing war in the Middle East and energy crisis. The article also briefly mentions SpectronRX securing $85M and news regarding Scinai Immunotherapeutics and Cardinal Health.Radiology BusinessRadiopharma firm secures $85M to expand domestic production of radioisotopesSpectronRx, an Indiana-based radiopharmaceutical company, secured $85 million from OrbiMed to expand U.S. radioisotope production. The funding supports a new 150,000-square-foot facility on a 14-acre acquisition, building on its existing 400,000-square-foot global manufacturing footprint.AuntMinnieSpectronRx raises $85M to expand radiopharmaceutical productionSpectronRx has secured $85 million in funding from investment firm OrbiMed to expand its medical isotope production and manufacturing capacity at its Grissom Aeroplex campus in Indiana. The company currently operates more than 400,000 square feet of radiopharmaceutical production space across facilities in Indiana, Connecticut, and Belgium, supporting over 300,000 patient doses annually. The long-term expansion plan provides capacity for more than one million square feet of production space.DOTmedSpectronRx raises $85 million to expand isotope production and manufacturing capacityIndianapolis-based radiopharmaceutical company SpectronRx has secured $85 million in financing from healthcare investment firm OrbiMed to expand isotope production and contract manufacturing operations at its Grissom Aeroplex campus in Indiana. The funding will support scaling production of medical isotopes including actinium-225, lutetium-177, and fluorine-18 used in oncology and diagnostic applications, with the 34-acre site now featuring roughly 200,000 square feet of GMP-compliant manufacturing space. OrbiMed cited supply reliability and integrated manufacturing as key factors behind the investment, noting that reliable access to high-quality medical isotopes remains a critical constraint in the radiopharmaceutical industry.